Category Archives: Pharma & Biotech

Pharma & Biotech Press Releases & News distributed via EuropaWire

OMRON Healthcare presenta los nuevos tensiómetros con tecnología de detección de fibrilación auricular (FA) e inteligencia artificial (IA), que se lanzarán en Europa en septiembre de 2024

EL NUEVO ALGORITMO AFIB INTELLISENSE DETECTA UNA POSIBLE FIBRILACIÓN AURICULAR EN CADA CONTROL DE PRESIÓN, MEJORANDO LA DETECCIÓN TEMPRANA Y LA POSIBLE PREVENCIÓN DE COMPLICACIONES GRAVES (NOTICIA EN BREVE) OMRON Healthcare ha lanzado nuevos tensiómetros equipados con tecnología de detección … Read the full press release

AstraZeneca Presents New Data at IDWeek 2024, Showcasing Progress in Respiratory Disease Prevention and Vaccine Innovation

(IN BRIEF) AstraZeneca presented significant advancements in the prevention of infectious diseases at IDWeek 2024, showcasing its dedication to addressing respiratory infections caused by RSV, hMPV, and COVID-19. The company revealed promising data across its portfolio, including Beyfortus, an antibody … Read the full press release

Boehringer Ingelheim and WHO Foundation Collaborate to Boost Global Healthcare Access and Suicide Prevention Efforts

(IN BRIEF) Boehringer Ingelheim and the WHO Foundation have partnered to promote equitable healthcare access and suicide prevention, with a focus on vulnerable communities in the Americas. Boehringer Ingelheim pledged $5 million to support WHO’s 2025–2028 General Program of Work … Read the full press release

EIB Global Invests €2 Million in Vaccine Development at Akagera Medicines in Rwanda

(IN BRIEF) The European Investment Bank (EIB Global) has committed €2 million to support Akagera Medicines Africa Limited in Rwanda, facilitating the early-stage development of vaccines for infectious diseases, including tuberculosis, HIV, Ebola, and Lassa fever. This funding aims to … Read the full press release

University of Liverpool and Roche Diagnostics Unite to Drive Health Innovation and Address Inequalities

(IN BRIEF) The University of Liverpool has signed a Memorandum of Understanding (MoU) with Roche Diagnostics UK and Ireland to enhance research and innovation focused on improving health outcomes and addressing health inequalities. This partnership aims to align with Roche’s … Read the full press release

GSK Reports Promising Phase III Findings for Depemokimab in Treating Chronic Rhinosinusitis with Nasal Polyps

(IN BRIEF) GSK plc has announced positive results from its Phase III ANCHOR trials for depemokimab, a biologic treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). The trials demonstrated a significant reduction in nasal polyp size and nasal obstruction after … Read the full press release

Roche’s Evrysdi Shows Remarkable Motor and Cognitive Outcomes in Children with SMA After Two Years of Early Treatment

(IN BRIEF) Roche has announced positive two-year data from its RAINBOWFISH study, showcasing the effectiveness of Evrysdi® (risdiplam) in treating children with spinal muscular atrophy (SMA) when administered before symptoms appear. The study revealed that most children achieved key motor … Read the full press release

Enhertu by AstraZeneca and Daiichi Sankyo Approved in China as First HER2-Directed Therapy for Metastatic Lung Cancer

(IN BRIEF) AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has received conditional approval in China for the treatment of patients with unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC) with HER2 (ERBB2) mutations who have previously undergone systemic … Read the full press release

Merck Opens €290 Million Biosafety Testing Facility in Rockville to Enhance Drug Safety and Accelerate Testing Timelines

(IN BRIEF) Merck has officially opened a new €290 million biosafety testing facility in Rockville, Maryland, designed to meet the increasing global demand for biosafety testing services. This state-of-the-art facility consolidates various operations, including biosafety testing, analytical development, and cell … Read the full press release

Roche Secures CE Certification for Groundbreaking Companion Diagnostic Aiding Gastric Cancer Treatment

(IN BRIEF) Roche has announced the CE certification of its VENTANA CLDN18 (43-14A) RxDx Assay, marking a significant advancement in companion diagnostics for patients with gastric and gastroesophageal junction (GEJ) adenocarcinoma. This diagnostic tool enables clinicians to identify patients who … Read the full press release

NIB Supports FinVector’s New Gene Therapy Facility in Kuopio to Enhance Cancer Treatment Capabilities

(IN BRIEF) FinVector, a leading biopharmaceutical company, has inaugurated a cutting-edge production facility in Kuopio, Finland, aimed at manufacturing gene therapy products. The new Finport facility, which is set to become one of the world’s largest for such therapies, represents … Read the full press release

Novo Nordisk Launches Global Childhood Obesity Initiative to Support Healthier Urban Communities

(IN BRIEF) Novo Nordisk has launched the Childhood Obesity Prevention Initiative, aimed at combating rising obesity rates among children in underserved urban communities across six cities worldwide. Backed by an investment of over 250 million Danish kroner and a coalition … Read the full press release

QIAGEN and Neo4j Strengthen Partnership to Revolutionize Biomedical Data Analysis in Biopharma Industry

(IN BRIEF) QIAGEN Digital Insights has announced an expanded partnership with Neo4j, aiming to enhance biomedical data analysis for the biopharmaceutical industry. This collaboration will integrate Neo4j’s graph database and machine learning capabilities with QIAGEN’s extensive biomedical knowledge base. By … Read the full press release

Fabentech Secures €20 Million EIB Loan to Bolster Pandemic Preparedness and Biological Threat Response

(IN BRIEF) Fabentech, a French biopharmaceutical company, has secured a €20 million loan from the European Investment Bank (EIB) through the HERA Invest initiative. The funding will support Fabentech’s research, bioproduction, and expansion of its FabShield® technology, which focuses on … Read the full press release

Early Success: AstraZeneca’s Airsupra Proves Highly Effective in Reducing Severe Asthma Risks in Phase III Trial

(IN BRIEF) AstraZeneca’s inhaled rescue medication, Airsupra (albuterol/budesonide), has shown significant efficacy in reducing the risk of severe asthma exacerbations in patients with intermittent or mild persistent asthma, according to high-level results from the BATURA Phase IIIb trial. The trial … Read the full press release

AstraZeneca and Daiichi Sankyo’s Enhertu Receives Priority Review for HER2-Low and Ultralow Breast Cancer Patients Pre-Chemotherapy

(IN BRIEF) AstraZeneca and Daiichi Sankyo announced that their drug Enhertu (trastuzumab deruxtecan) has been granted Priority Review by the US FDA for treating patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer who have previously undergone endocrine therapy. … Read the full press release

Fresenius Kabi and Formycon Receive European Approval for Ustekinumab Biosimilar FYB202

(IN BRIEF) Fresenius Kabi, in collaboration with Formycon, has received approval from the European Commission (EC) for FYB202, a biosimilar of ustekinumab (marketed as Stelara® by Johnson & Johnson). This biosimilar is approved for the treatment of serious inflammatory diseases. … Read the full press release

Fresenius Kabi’s Ustekinumab Biosimilar Otulfi® Secures European Approval for Treating Inflammatory Diseases

(IN BRIEF) Fresenius Kabi, in partnership with Formycon AG, has received European Commission approval for Otulfi®, a biosimilar of ustekinumab. This new product, authorized for both subcutaneous and intravenous formulations, will treat inflammatory conditions such as Crohn’s disease, plaque psoriasis, … Read the full press release

Pharma Leaders Unite to Promote Ready-to-Use Packaging Solutions, Enhancing Safety and Efficiency

(IN BRIEF) SCHOTT Pharma, Gerresheimer, and Stevanato Group have formed the “Alliance for RTU” to promote the adoption of ready-to-use (RTU) vials and cartridges within the pharmaceutical industry. This strategic alliance aims to streamline pharmaceutical manufacturing, improve operational efficiency, and … Read the full press release

Roche’s Gazyva Shows Breakthrough Results in Treating Lupus Nephritis, Offering Hope for Kidney Disease Patients

(IN BRIEF) Roche has announced positive results from its phase III REGENCY study, showing that its drug Gazyva®/Gazyvaro® (obinutuzumab) significantly outperformed standard therapy in treating active lupus nephritis. The study found that patients receiving Gazyva/Gazyvaro, in combination with standard therapies, … Read the full press release